Fertility Preservation in Young Women With Breast Cancer: A Review
- Author:
Yeon Hee HONG
1
;
Changhee PARK
;
Haerin PAIK
;
Kyung-Hun LEE
;
Jung Ryeol LEE
;
Lee HAN
;
Seho PARK
;
Seockhoon CHUNG
;
Hee Jeong KIM
Author Information
- Publication Type:Review Article
- From:Journal of Breast Cancer 2023;26(3):221-242
- CountryRepublic of Korea
- Language:English
- Abstract: Fertility preservation is a major concern in young patients diagnosed with breast cancer and planning to receive multimodality treatment, including gonadotoxic chemotherapy with or without age-related decline through long-term endocrine therapy. Most breast cancer patients undergo multimodality treatments; many short-term and long-term side effects arise during these therapies. One of the most detrimental side effects is reduced fertility due to gonadotoxic treatments with resultant psychosocial stress. Cryopreservation of oocytes, embryos, and ovarian tissue are currently available fertility preservation methods for these patients. As an adjunct to these methods, in vitro maturation or gonadotropinreleasing hormone agonist could also be considered. It is also essential to communicate well with patients in the decision-making process on fertility preservation. It is essential to refer patients diagnosed with breast cancer on time to fertility specialists for individualized treatment, which may lead to desirable outcomes. To do so, a multimodal team-based approach and in-depth discussion on the treatment of breast cancer and fertility preservation is crucial. This review aims to summarize infertility risk related to currently available breast cancer treatment, options for fertility preservation and its details, barriers to oncofertility counseling, and psychosocial issues.
